These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34565708)

  • 1. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
    Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
    Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
    Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
    Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
    Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
    Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
    Walsh A; Kelly DR; Vaid YN; Hilliard LM; Friedman GK
    Pediatr Blood Cancer; 2010 Dec; 55(6):1217-20. PubMed ID: 20979179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
    Strouse JJ; Spevak M; Mack AK; Arceci RJ; Small D; Loeb DM
    Pediatr Blood Cancer; 2005 Apr; 44(4):407-11. PubMed ID: 15602719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic presentation of a renal medullary carcinoma in a young woman.
    Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
    Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil.
    Maroja Silvino MC; Venchiarutti Moniz CM; Munhoz Piotto GH; Siqueira S; Galapo Kann A; Dzik C
    Rare Tumors; 2013; 5(3):e44. PubMed ID: 24179656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
    Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
    Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
    Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
    BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
    Carter SA; Walker AN
    J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives].
    Diao B; Paule B; Esquivel S; Abbou CC; Salomon L; De La Taille A
    Prog Urol; 2010 Jul; 20(7):538-41. PubMed ID: 20656278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.
    Geller JI; Cost NG; Chi YY; Tornwall B; Cajaiba M; Perlman EJ; Kim Y; Mullen EA; Glick RD; Khanna G; Daw NC; Ehrlich P; Fernandez CV; Dome JS;
    Cancer; 2020 Dec; 126(23):5156-5164. PubMed ID: 32926409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Medullary Carcinoma: The Zebra Amongst the Horses.
    Dalela D; Batie S; Carolan A; Schlomer B; Collins R; Jacobs M
    Urology; 2024 May; 187():78-81. PubMed ID: 38467288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.
    Peyromaure M; Thiounn N; Scotté F; Vieillefond A; Debré B; Oudard S
    J Urol; 2003 Oct; 170(4 Pt 1):1138-40. PubMed ID: 14501710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.
    Rathmell WK; Monk JP
    Urology; 2008 Sep; 72(3):659-63. PubMed ID: 18649931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.